scispace - formally typeset
Search or ask a question
Topic

Juvenile dermatomyositis

About: Juvenile dermatomyositis is a research topic. Over the lifetime, 1369 publications have been published within this topic receiving 31486 citations. The topic is also known as: JDM & childhood Dermatomyositis.


Papers
More filters
Journal ArticleDOI
TL;DR: In this paper, the frequency and ethnic variation of Henoch-Schonlein purpura, Kawasaki disease, and rarer vasculitides during childhood are not well characterised.

630 citations

Journal ArticleDOI
TL;DR: Although there were no significant differences in the 2 treatment arms for the primary and secondary end points, 83% of adult and juvenile myositis patients with refractory disease met the DOI, and individual CSMs improved in both groups throughout the 44-week trial.
Abstract: The idiopathic inflammatory myopathies (IIM) are a heterogeneous group of acquired disorders characterized by chronic inflammation of striated muscle leading to predominantly proximal muscle weakness. The most common subsets of IIM include adult polymyositis (PM), adult and juvenile dermatomyositis (DM), myositis in overlap with cancer or another connective tissue disease and inclusion body myositis (IBM). The IIM are frequently associated with constitutional symptoms and commonly involve other organ systems including the skin, joints, lungs, gastrointestinal tract and heart. They are rare with an estimated incidence of 4-10 cases/million population per year and a bimodal incidence pattern reflecting childhood onset of juvenile DM (JDM) and a later peak in adulthood [1]. Although the precise pathogenesis is unknown, the IIM likely result from immune-mediated processes initiated by environmental factors in genetically susceptible individuals [2]. Factors strongly supporting their autoimmune basis include: the association of myositis with other autoimmune diseases such as Hashimoto thyroiditis, Grave’s disease and various connective tissue diseases, the high frequency of circulating serum autoantibodies, and their response to immunosuppressive (IS) or immunomodulatory therapy. The treatment of IIM is challenging, complicated by its rarity and heterogeneity as well as the lack of controlled trials and partially validated outcome measures. Most studies involve single referral centers using cross-sectional and retrospective analyses of small numbers of treatmentrefractory patients observed for relatively short time periods. In addition, widely disparate inclusion criteria have complicated the assessment of treatment response, as disease damage and the inclusion of misdiagnosed patients contribute to suboptimal therapeutic outcomes. Although glucocorticoids have not been formally tested in controlled trials, expert consensus is that they are the primary therapy to be followed by a variety of immunosuppressive or immunomodulatory agents alone or in combination [2]. Rituximab, a B cell depleting agent long recognized as an effective therapy for B cell lymphomas, has gained increased favor in the treatment of many autoimmune diseases and is FDA-approved for use in rheumatoid arthritis [3] as well as granulomatosis with polyangiitis and microscopic polyangiitis [4]. The effectiveness of rituximab in PM and DM has been suggested by case reports and case series in adult and pediatric patients with refractory disease [5-9]. B cells play a critical role in the initiation and propagation of the immune response and are implicated in the pathogenesis of myositis. They localize to the perivascular region of DM muscle and are found in the inflammatory infiltrates of both PM and DM [10]. In addition to functioning as the precursor of autoantibody-producing plasma cells, B cells present antigen to T cells and secrete proinflammatory cytokines [10]. Therefore, based on the autoimmune characteristics of myositis and the aforementioned immunopathogenic role of the B cell, the Rituximab in Myositis (RIM) trial assessed the effectiveness of rituximab in refractory adult PM and adult and juvenile DM using validated measures of myositis disease activity and damage, a consensus-driven definition of improvement [11-13] and a unique randomized placebo-phase trial design [14, 15].

501 citations

Journal ArticleDOI
TL;DR: Activation of dendritic cells with upregulation of genes induced by type-1 interferon (alpha) in muscle and peripheral blood seems to be central to disease pathogenesis and treatment often includes combinations of corticosteroids, methotrexate, and other immunosuppressive agents.

354 citations

Journal ArticleDOI
TL;DR: This study provides evidence for sex, and possibly racial differences in the risk of juvenile DM in the US and suggests girls were affected more than boys during the 4-year period of the study.
Abstract: Objective To estimate the incidence of juvenile dermatomyositis (juvenile DM) in the United States between 1995 and 1998. Methods Physician referrals to the National Institute of Arthritis and Musculoskeletal and Skin Diseases Juvenile Dermatomyositis Research Registry and the National Pediatric Rheumatology Disease Registry from Indiana University were utilized for a 2-source capture-recapture estimation of Juvenile DM annual incidence. Results For children 2–17 years of age, the estimated annual incidence rates from 1995 to 1998 in the US ranged from 2.5 to 4.1 juvenile DM cases per million children, and the 4-year average annual rate was 3.2 per million children (95% confidence interval 2.9–3.4). Estimated annual incidence rates by race were 3.4 for white non-Hispanics, 3.3 for African American non-Hispanics, and 2.7 for Hispanics. During the 4-year period of the study, completeness of ascertainment for the combined registries ranged from 56% to 86% and girls were affected more than boys (ratio 2.3:1). Conclusion This study provides evidence for sex, and possibly racial differences in the risk of juvenile DM in the US.

289 citations


Network Information
Related Topics (5)
Rheumatoid arthritis
44.5K papers, 1.2M citations
84% related
Arthritis
46.7K papers, 1.6M citations
82% related
Autoimmune disease
16.9K papers, 709.2K citations
81% related
Lupus erythematosus
21.7K papers, 893.7K citations
81% related
Autoantibody
21.7K papers, 745.3K citations
79% related
Performance
Metrics
No. of papers in the topic in previous years
YearPapers
202375
2022161
202195
202075
201969
201862